Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients.
- DOI
- 10.1097/hs9.0000000000000829
- Published
- 2023 Feb
- Container
- HemaSphere
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1097/hs9.0000000000000829,
title = {Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients.},
author = {Ocio EM and Bringhen S and Martinez-Lopez J and San-Miguel J and Oliva S and Rodriguez-Otero P and Le Roux N and Dong Y and Doroumian S and Macé S and Mateos MV},
year = {2023},
journal = {HemaSphere},
doi = {10.1097/hs9.0000000000000829},
url = {https://doi.org/10.1097/hs9.0000000000000829}
}RIS
TY - JOUR TI - Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients. AU - Ocio EM AU - Bringhen S AU - Martinez-Lopez J AU - San-Miguel J AU - Oliva S AU - Rodriguez-Otero P AU - Le Roux N AU - Dong Y AU - Doroumian S AU - Macé S AU - Mateos MV PY - 2023 JO - HemaSphere DO - 10.1097/hs9.0000000000000829 UR - https://doi.org/10.1097/hs9.0000000000000829 ER -
APA
EM, O., S, B., J, M., J, S., S, O., P, R., N, L. R., Y, D., S, D., S, M., & MV, M. (2023). Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients.. HemaSphere. https://doi.org/10.1097/hs9.0000000000000829
Source records
- pubmed · retrieved 2026-09-26T04:50:37.647Z